Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy 2QFY02 net up 22% - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 9, 2001

    Ranbaxy 2QFY02 net up 22%

    Ranbaxy Laboratories Ltd has posted marginally better than expected growth in topline in 2QFY02 on the back of strong growth in exports. US exports grew by 53% to touch US $ 24.5 m. There was however a 120 basis points drop in operating margins. The drop in operating margins appears due to below average growth in anti-infective segment, which contributes around 45% of the domestic formulations revenues.

    (Rs m) 2QFY01 2QFY02 Change
    Net Sales 4,236 4,993 17.9%
    Other Income 99 123 24.2%
    Expenditure 3,617 4,323 19.5%
    Operating Profit (EBDIT) 619 670 8.2%
    Operating Profit Margin (%) 14.6% 13.4%  
    Interest 158 138 -12.7%
    Depreciation 123 128 4.1%
    Profit before Tax 437 527 20.6%
    Tax 33 34 3.0%
    Profit after Tax/(Loss) 404 493 22.0%
    Net profit margin (%) 9.5% 9.9%  
    No. of Shares (eoy) (m) 41.4 115.9  
    Earnings per share* 39.0 17.0  
    Current P/e ratio   28.3  

    Ranbaxy's global sales for the period 1HFY02 stood at US$ 269 m registering a growth of 17%. The company's international operations are expected to perform well in the coming quarters on the back of the 38 approved product basket for the US generics market. Though each filing is not large, collectively it is expected to provide a fillip to the company's revenues.

    The company has recently got a six month exclusivity for its generic dosage of Advil, an OTC cold and sinus drug with a market size of around US$ 50 m. Further, Ranbaxy claims to be only company to file for US FDA approval for Ceftum (Cefuroxime Axetil). The litigation for the same is on in the US and the court decision is expected soon. The patent court decision could provide a big fillip to the company's financials if the decision turns out in company's favour considering that the market for Cefuroxime Axetil is more than US$ 400 m. Ranbaxy can mop a fair share of this market if the decision turns out in its favour.

    On the R&D front, Cipro-D molecule licensed to Bayer is in the last, phase-III of clinical trials both in India and the US. The company is expected to soon announce launch of the same in India. Further, the company's BPH molecule (RBx 2258), has actively moved forward in Clinical Phase-II studies in India.

    At the current market price of Rs 482, the stock is trading at 21 times our expected earnings for FY02. In the immediate term there could be several triggers for the stock including a spurt in profitability from international operations, launch of Cipro-D and outlicensing of its BPH molecule. However, on the domestic front the company will have to reduce its dependence on anti-infectives quickly to provide a much needed boost to its operating margins.



    Equitymaster requests your view! Post a comment on "Ranbaxy 2QFY02 net up 22%". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks